<DOC>
	<DOC>NCT02882789</DOC>
	<brief_summary>Primary - To investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous dosage form of LCB01-0371 comparing to oral dosage in Healthy Male Volunteers Secondary â€¢ To investigate the absolute bio availability of LCB01-0371 after a single intravenous dose</brief_summary>
	<brief_title>IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>1. Healthy Male between 19 and 39 years of age at the time of screening 2. Subjects with body mass index (BMI) between 19 and 27 at the time of screening 3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 28 days of study completion 4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements 1. History of gastrointestinal problem (e.g. Crohn's disease, gastrointestinal ulcer) which is affect to absorption OR surgical history except appendectomy, herniotomy 2. History of allergy, cardiovascular, peripheral vascular, skin, mucous membrane, eyes, otorhinolaryngologic, respiratory, musculoskeletal, infectious disease, gastroenterologic, liver, billiary, endocrinologic, kidney, genitourinary, neuropsychiatric, hematooncologic problem(s) or fracture etc.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>